NextCell Pharma AB (DE:65G)

FRANKFURT:65G

65G

NextCell Pharma AB

RESEARCH TOOLSreports

Want to see DE:65G full AI Analyst Report?

NextCell Pharma AB (65G) Price & Analysis

0 Followers

65G Stock Chart & Stats

€0.05

>-€0.01(-2.19%)

At close: Jan 08 4:00 PM EST

€0.05

>-€0.01(-2.19%)

Day’s Range― - ―

52-Week Range€0.05 - €0.17

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€11.55M

Enterprise Value€100.95M

Total Cash (Recent Filing)€26.03M

Total Debt (Recent Filing)€0.00

Price to Earnings (P/E)―

Beta-0.39

Next Earnings

May 28, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.45

Shares Outstanding111,392,960

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.13

Price to Book (P/B)1.36

Price to Sales (P/S)8.24

P/FCF Ratio-2.09

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.04

Revenue Forecast (FY)€1.51M

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetA zero-debt capital structure materially reduces refinancing and interest-rate risk, giving management flexibility to fund R&D or pivot via equity or partnerships. Over a 2–6 month horizon this preserves optionality and reduces fixed-cost pressure compared with leveraged peers.

Focused Cell-therapy PlatformA clear focus on MSC-derived therapies and clinical development in inflammatory/autoimmune indications concentrates resources and expertise. This specialization supports durable competitive differentiation, regulatory pathway clarity and partnership appeal in regenerative medicine over the medium term.

Favorable FCF Trend Vs Prior YearAlthough FCF remains negative, the reported improvement in trailing free cash flow suggests operational timing or cost control gains. If sustained, this reduces future funding needs and lengthens runway, improving strategic stability into the next several quarters.

Bears Say

Persistent Heavy LossesContinued negative gross profit and deep operating losses erode capital and make reaching breakeven difficult without meaningful revenue expansion or cost cuts. Over months, persistent unprofitability increases reliance on external financing and constrains reinvestment capacity.

Significant Cash BurnSustained operating and free cash outflows indicate the company is consuming capital faster than it generates it. This structural cash burn necessitates recurring funding rounds or partnerships, raising dilution or execution risk and limiting long-term independent growth prospects.

Eroding Equity BaseA shrinking equity base reduces the balance-sheet buffer against losses and heightens solvency risk if operating losses persist. Over the medium term this weakens negotiating leverage in financing rounds and increases the probability of dilutive capital raises or strategic transactions.

65G FAQ

What was NextCell Pharma AB’s price range in the past 12 months?

NextCell Pharma AB lowest stock price was €0.05 and its highest was €0.17 in the past 12 months.

What is NextCell Pharma AB’s market cap?

NextCell Pharma AB’s market cap is €11.55M.

When is NextCell Pharma AB’s upcoming earnings report date?

NextCell Pharma AB’s upcoming earnings report date is May 28, 2026 which is in 5 days.

How were NextCell Pharma AB’s earnings last quarter?

NextCell Pharma AB released its earnings results on Oct 30, 2025. The company reported -€0.007 earnings per share for the quarter, beating the consensus estimate of -€0.009 by €0.002.

Is NextCell Pharma AB overvalued?

According to Wall Street analysts NextCell Pharma AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does NextCell Pharma AB pay dividends?

NextCell Pharma AB does not currently pay dividends.

What is NextCell Pharma AB’s EPS estimate?

NextCell Pharma AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does NextCell Pharma AB have?

NextCell Pharma AB has 111,392,960 shares outstanding.

What happened to NextCell Pharma AB’s price movement after its last earnings report?

NextCell Pharma AB reported an EPS of -€0.007 in its last earnings report, beating expectations of -€0.009. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of NextCell Pharma AB?

Currently, no hedge funds are holding shares in DE:65G

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

NextCell Pharma AB

NextCell Pharma AB, a biopharmaceutical company, engages in the research and development of novel stem cell therapies in Sweden. The company develops ProTrans, a drug candidate comprising stem cells primarily for treating autoimmune and inflammatory diseases. It also provides Cellaviva, a stem cell bank for the family-saving of stem cells from umbilical cord blood and umbilical cord tissue. NextCell Pharma AB was incorporated in 2014 and is based in Huddinge, Sweden.